The therapeutic success of immune checkpoint blockade in classical Hodgkin lymphoma (cHL) has largely been attributed to the high prevalence of 9p24.1 amplification and the enhanced PD-1/PD-L1/2 expression on tumor cells and in the TME in this disease. Here, PDCD1 is linked to neoplasm.